78 results
8-K
EX-10.1
x8ffs17n
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
cyf1s1i4schtrd4
14 Feb 24
Other Events
4:11pm
424B5
f1t5z7 t2vii2h
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
68a g0x2aattct1s8sd
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
li46wc4irqia y475
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
co8cmx1
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
EX-4.3
91fufbn1d21yfo
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
pv8ve 61l
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
424B3
b99 5t3p6ue2aqbjai
28 Aug 23
Prospectus supplement
9:10am
S-4/A
vebejm frxjrek
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
ym0mouvlfin03
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
S-4
EX-10.42
luor9m5f o7l
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm